Merck's Keytruda Doubled PFS In Some Colorectal Cancer Patients In ASCO Late-Breaker

Pembrolizumab should be considered the new standard of care as first-line therapy in patients with microsatellite instability high (MSI-H) metastatic colorectal cancer, KEYNOTE-177 investigator André said.